Estimating The Economic and Clinical Benefits of Mirabegron Versus Antimuscarinics for The Treatment of Overactive Bladder (OAB) in The United Kingdom (UK)
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.996
https://www.valueinhealthjournal.com/article/S1098-3015(16)32362-2/fulltext
Title :
Estimating The Economic and Clinical Benefits of Mirabegron Versus Antimuscarinics for The Treatment of Overactive Bladder (OAB) in The United Kingdom (UK)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32362-2&doi=10.1016/j.jval.2016.09.996
First page :
A518
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
934